Home › Funds › Aisling Capital Management LP › BBIO
Aisling Capital Management LP position in BBIO
BRIDGEBIO PHARMA INC · Health Care
Aisling Capital Management LP reported holding 3,089,611 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$203.3M, representing 67.92% of its reported portfolio and ranking #1 among its reported holdings. Aisling Capital Management LP has disclosed BBIO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Aisling Capital Management LP's BBIO position evolved
Aisling Capital Management LP first disclosed a stake in BBIO in Q3 2023 at 6,068,125 shares (US$160.0M). The position peaked in Q4 2025 at 5,089,611 shares, worth US$389.3M. Across 13 filings, Aisling Capital Management LP increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 3,089,611 shares valued at US$203.3M — a reduction of -1,500,000 shares quarter over quarter.. Notable position changes include a 33% trim in Q3 2026 (shares rose 21% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 6.07M | $160.02M | New |
| Q4 2023 | 6.07M | $244.97M | Hold |
| Q1 2024 | 6.07M | $187.63M | Hold |
| Q2 2024 | 6.07M | $153.71M | Hold |
| Q3 2024 | 6.07M | $154.49M | Hold |
| Q4 2024 | 6.07M | $166.51M | Hold |
| Q1 2025 | 6.07M | $209.78M | Hold |
| Q2 2025 | 6.07M | $262.02M | Hold |
| Q3 2025 | 6.09M | $316.29M | Hold |
| Q4 2025 | 5.09M | $389.30M | Reduce |
| Q1 2026 | 5.09M | $377.95M | Hold |
| Q2 2026 | 4.59M | $341.83M | Reduce |
| Q3 2026 | 3.09M | $203.30M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBIO and 13F data
BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 40 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBIO
- Jupiter Topco LLC 14.11M sh · $1.05B · Q2 2026
- Janus Henderson Group 13.18M sh · $978.61M · Q1 2026
- Farallon Capital Management 10.74M sh · $800.14M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 10.74M sh · $800.14M · Q2 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.95M sh · $741.02M · Q2 2026
- SC US (TTGP), LTD. 1.86M sh · $138.56M · Q2 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 69.87M sh · $124.49M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.55M sh · $115.31M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.37M sh · $102.27M · Q2 2026
- Hood River Capital Management LLC 1.35M sh · $100.36M · Q2 2026
- DeepCurrents Investment Group LLC 50.24M sh · $89.75M · Q2 2026
More on Aisling Capital Management LP
FAQ
How long has Aisling Capital Management LP held BBIO?
Aisling Capital Management LP has disclosed BBIO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Aisling Capital Management LP's current position in BBIO?
As of Q3 2026, Aisling Capital Management LP holds 3.09M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $203.30M, representing 67.92% of its reported portfolio and ranking #1.
Has Aisling Capital Management LP been buying or selling BBIO?
In the latest 13F filing (Q3 2026), Aisling Capital Management LP reduced its position in BBIO. The position peaked in Q4 2025 at 5.09M shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.